1st Quarter - Report
STANTON PARK GROUP for VERTEX PHARMACEUTICALS INCORPORATED
Firm
Income
$30,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions). Awareness of Cystic Fibrosis (no specific bills)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES DERDERIAN | — |
| VALERIE HENRY | — |
| PATRICK LYDEN | — |
| RICHARD MATHER RUSSELL | — |
| ERIN STRAWN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.